ImmunoGen (IMGN) Shares are Up 6.39%

ImmunoGen (IMGN) has been under a strong bear grip, hence the stock is down -4.35% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 5.83% in the past 1 week. The stock has risen by 6.39% in the past week indicating that the buyers are active at lower levels, but the stock is down -6.29% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 1.46% and the 50-Day Moving Average is 3.04%.The 200 Day SMA reached 58.52% ImmunoGen, Inc. has dropped 14.76% during the last 3-month period . Year-to-Date the stock performance stands at -79.15%.


ImmunoGen (IMGN) : Average target price received by ImmunoGen (IMGN) is $5.9 with an expected standard deviation of $2.41. The most aggressive target on the stock is $9, whereas the most downbeat target is $3. 5 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy. ImmunoGen (NASDAQ:IMGN): The stock opened at $2.81 and touched an intraday high of $2.87 on Friday. During the day, the stock corrected to an intraday low of $2.75, however, the bulls stepped in and pushed the price higher to close in the green at $2.83 with a gain of 1.80% for the day. The total traded volume for the day was 4,400,905. The stock had closed at $2.83 in the previous trading session.

ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Companys clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Companys partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Companys collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Companys compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *